Published in Hepatitis Weekly, June 19th, 2006
Known as the PROTECT study, the trial is targeted to enroll 125 HCV patients at approximately 28 liver transplant centers nationwide.
Hepatitis C is currently the indication for liver transplantation in the United States, (U.S. Centers for Disease Control and Prevention) and more than 17,000 Americans are awaiting liver transplants for all diagnoses...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.